collection
MENU ▼
Read by QxMD icon Read
search

YUEJN- VascPharm

shared collection
8 papers 0 to 25 followers
By Jianing Yue Attending Vascular Surgeon, Zhongshan Hospital Fudan University, Shanghai, China
https://www.readbyqxmd.com/read/26620397/meta-analysis-of-studies-evaluating-the-effect-of-cilostazol-on-major-outcomes-after-carotid-stenting
#1
REVIEW
George Galyfos, Georgios Geropapas, Fragiska Sigala, Konstantina Aggeli, Argiri Sianou, Konstantinos Filis
PURPOSE: To evaluate the effect of cilostazol on major outcomes after carotid artery stenting (CAS). METHODS: A systematic literature review was conducted conforming to established criteria in order to identify articles published prior to May 2015 evaluating major post-CAS outcomes in patients treated with cilostazol vs patients not treated with cilostazol. Major outcomes included in-stent restenosis (ISR) within the observation period, the revascularization rate, major/minor bleeding, and the myocardial infarction/stroke/death rate (MI/stroke/death) at 30 days and within the observation period...
February 2016: Journal of Endovascular Therapy
https://www.readbyqxmd.com/read/24239116/platelet-inhibition-by-adjunctive-cilostazol-suppresses-the-frequency-of-cerebral-ischemic-lesions-after-carotid-artery-stenting-in-patients-with-carotid-artery-stenosis
#2
Ichiro Nakagawa, Takeshi Wada, Hun Soo Park, Fumihiko Nishimura, Syuichi Yamada, Hiroyuki Nakagawa, Kimihiko Kichikawa, Hiroyuki Nakase
OBJECTIVE: Optimal platelet inhibition is an important therapeutic adjunct in patients with carotid artery stenosis undergoing carotid artery stenting (CAS). Clopidogrel resistance is associated with increased periprocedural thromboembolic complications from neurovascular stent placement procedures. The addition of cilostazol to dual antiplatelet therapy (DAT) has been reported to reduce platelet reactivity and to improve clinical outcomes after percutaneous coronary intervention. This study was undertaken to evaluate the impact of adjunctive cilostazol in patients with CAS...
March 2014: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/23932803/statin-use-and-lower-extremity-amputation-risk-in-nonelderly-diabetic-patients
#3
RANDOMIZED CONTROLLED TRIAL
Min-Woong Sohn, Judith L Meadows, Elissa H Oh, Elly Budiman-Mak, Todd A Lee, Neil J Stone, William B Pearce
OBJECTIVE: To examine the association between use of statin and nonstatin cholesterol-lowering medications and risk of nontraumatic major lower extremity amputations (LEAs) and treatment failure (LEA or death). METHODS: A retrospective cohort of patients with Type I and Type 2 diabetes mellitus (diabetes) was followed for 5 years between 2004 and 2008. The follow-up exposure duration was divided into 90-day periods. Use of cholesterol-lowering agents, diabetic medications, hemoglobin A1c, body mass index, and systolic and diastolic blood pressures were observed in each period...
December 2013: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/23891491/discontinuation-of-preoperative-clopidogrel-is-unnecessary-in-peripheral-arterial-surgery
#4
COMPARATIVE STUDY
Carlos Saadeh, Julien Sfeir
OBJECTIVE: The optimal management of preoperative clopidogrel remains controversial, as vascular surgeons are increasingly encountering patients treated with clopidogrel as part of dual antiplatelet therapy. Current practice differs considerably, from cessation of the medication at least 5 days before surgery to proceeding with surgery without delay. The purpose of this prospective, nonrandomized, comparative study was to determine the effect of preoperative exposure to clopidogrel and aspirin on perioperative bleeding complications in patients undergoing open arterial surgery...
December 2013: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/23732713/aspirin-versus-low-molecular-weight-heparin-for-extended-venous-thromboembolism-prophylaxis-after-total-hip-arthroplasty-a-randomized-trial
#5
RANDOMIZED CONTROLLED TRIAL
David R Anderson, Michael J Dunbar, Eric R Bohm, Etienne Belzile, Susan R Kahn, David Zukor, William Fisher, Wade Gofton, Peter Gross, Stephane Pelet, Mark Crowther, Steven MacDonald, Paul Kim, Susan Pleasance, Nicki Davis, Pantelis Andreou, Philip Wells, Michael Kovacs, Marc A Rodger, Tim Ramsay, Marc Carrier, Pascal-Andre Vendittoli
BACKGROUND: The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. OBJECTIVE: To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA. DESIGN: Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically important difference of 2.0%. Randomization was electronically generated; patients were assigned to a treatment group through a Web-based program...
June 4, 2013: Annals of Internal Medicine
https://www.readbyqxmd.com/read/23660119/beta-blocker-use-and-clinical-outcomes-after-primary-vascular-surgery-a-nationwide-propensity-score-matched-study
#6
A Høgh, J S Lindholt, H Nielsen, L P Jensen, S P Johnsen
OBJECTIVE: To explore the associations between beta-blocker use and clinical outcomes (death, hospitalisation with myocardial infarction (MI) or stroke, major amputation and recurrent vascular surgery) after primary vascular reconstruction. METHODS: Patients who had primary vascular surgical or endovascular reconstruction due to symptomatic peripheral arterial disease, in Denmark between 1996 and 2007 were included. We obtained data on filled prescriptions, clinical outcomes and confounding factors from population-based healthcare registries...
July 2013: European Journal of Vascular and Endovascular Surgery
https://www.readbyqxmd.com/read/22514252/net-clinical-benefit-of-warfarin-in-patients-with-atrial-fibrillation-a-report-from-the-swedish-atrial-fibrillation-cohort-study
#7
Leif Friberg, Mårten Rosenqvist, Gregory Y H Lip
BACKGROUND: Known risk factors for bleeding during anticoagulant treatment are largely the same as those predicting thromboembolic events in patients with atrial fibrillation (AF). Our objective was to investigate how to maximize the likelihood of avoiding both stroke and bleeding. METHODS AND RESULTS: All 182 678 subjects with atrial fibrillation in the Swedish Hospital Discharge Register were studied for an average of 1.5 years (260 000 patient-years at risk)...
May 15, 2012: Circulation
https://www.readbyqxmd.com/read/18482817/cilostazol-reduces-restenosis-after-endovascular-therapy-in-patients-with-femoropopliteal-lesions
#8
RANDOMIZED CONTROLLED TRIAL
Osamu Iida, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, Masafumi Kitakaze, Seiki Nagata
BACKGROUND: Despite the recent development of endovascular therapy (EVT), a high incidence of restenosis remains as an unsolved issue in patients presenting with femoropopliteal lesions. We investigated whether cilostazol reduces restenosis after successful EVT for de novo femoropopliteal lesions. METHODS: This study was designed as a prospective, randomized, open-label, blinded end point study in a single institution. Between March 2004 and June 2005, we randomized 127 patients who were successfully treated with EVT for de novo femoropopliteal lesions to receive cilostazol (200 mg/d, n = 63) or ticlopidine (200 mg/d, n = 64) in addition to aspirin (100 mg/d)...
July 2008: Journal of Vascular Surgery
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"